Quantcast
 
New ETF Book by Larry Connors - Click here to read more


 

Owensboro Cancer Research Program awarded $2 million

Thu. October 02, 2008; Posted: 06:50 AM
Stocks RSS
Oct 02, 2008 (Messenger-Inquirer - McClatchy-Tribune Information Services via COMTEX) -- LSBC | Quote | Chart | News | PowerRating -- President Bush signed legislation Tuesday night, approving $2 million for research at the Owensboro Cancer Research Program.

That comes on top of $2 million earmarked for the program at Owensboro Medical Health System in last year's defense budget.

"These funds will provide the Owensboro Cancer Research Program with additional resources to better understand, treat and prevent cancer," U.S. Rep. Ron Lewis said in a news release. "This research is critical for the development of important new plant-based pharmaceuticals."

Keith Davis, the program's executive director, said the federal money will be used for further research into growing various vaccines in plants, primarily tobacco.

The OCRP hopes to eventually win federal contracts to produce specific vaccines for the government, he said.

Davis said he plans to visit federal laboratories to look for ways the OCRP can become more involved.

"We've put in proposals in the past," he said, "but they haven't been funded. We want to demonstrate that we can really do this."

Lewis has been working to support the plant-based pharmaceutical industry in Owensboro for years.

In 2001, he helped secure $2.5 million for Large Scale Biology, the California-based company that built what is now Kentucky BioProcessing's biopharmaceutical manufacturing facility in MidAmerica Airpark.

That money was for a program the Navy was working on with Large Scale and the National Institutes of Health to develop a way to take radiation-damaged bone marrow stem cells from people, clean them with the tobacco-based technology and replant the clean cells into the victim's bone marrow, Lewis said at the time.

He said in 2001 that the research funded by the appropriation was designed to "find cures for military members and civilians exposed to radiation, make progress on cancer cures and advances in stem cell research that do not involve the destruction of human embryos."

In 2002, Large Scale, which would dissolve in bankruptcy court four years later, was talking with federal officials about using its tobacco-produced vaccines to combat "viro-terrorism."

Company officials said the Owensboro plant could produce 250 million doses of a vaccine within 24 weeks, using 2,000 acres of tobacco in Daviess County and an equal amount in Homestead, Fla., and in South Carolina.

They estimated the cost of producing 250 million doses of vaccine at $30 million.

Davis said the OCRP and KBP are still interested in working with the government to produce vaccines.

"We can turn things around very quickly," he said.

The University of Louisville's Brown Cancer Center and the Owensboro Medical Health System created the Owensboro Cancer Research Program as a joint venture to develop cancer therapies using plant production systems.

Research is conducted in laboratories maintained by OMHS at the Mitchell Memorial Cancer Center.

"I have strongly supported this project since its inception," Lewis said in a news release.

Davis said the OCRP still hasn't received the 2007 appropriation.

"We're anticipating it at any time," he said. "It just takes a while to actually receive the money."

To see more of the Messenger-Inquirer, or to subscribe to the newspaper, go to http://www.messenger-inquirer.com. Copyright (c) 2008, Messenger-Inquirer, Owensboro, Ky. Distributed by McClatchy-Tribune Information Services. For reprints, email tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

For full details for LSBC click here.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Most Popular News
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.